• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

    10/23/23 6:44:39 AM ET
    $CET
    $DAWN
    $RMAX
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CET alert in real time by email

    Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Day One Biopharmaceuticals

    • The Trade: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) 10% owner Len Blavatnik acquired a total of 1,475,454 shares an average price of $10.15. To acquire these shares, it cost around $14.98 million.
    • What’s Happening: Day One Biopharmaceuticals submitted rolling new drug application to the FDA for tovorafenib in relapsed or progressive pediatric low-grade glioma.
    • What Day One Biopharmaceuticals Does: Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers.

    Central Securities

    • The Trade: Central Securities Corporation (NYSE:CET) Vice President Andrew J. O'Neill acquired a total of 1,954 shares at an average price of $35.80. To acquire these shares, it cost around $69,947.
    • What’s Happening: The company’s stock gained around 6% year-to-date.
    • What Central Securities Does: Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital.

    Don’t forget to check out our premarket coverage here

    RE/MAX Holdings

    • The Trade: RE/MAX Holdings, Inc. (NYSE:RMAX) 10% owner Magnolia Group LLC bought a total of 15,000 shares at an average price of $10.74. To acquire these shares, it cost around $161,100.
    • What’s Happening: RE/MAX Hldgs posted in-line earnings for the second quarter.
    • What RE/MAX Holdings Does: RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises.

    Check This Out: Top 4 Health Care Stocks That May Rocket Higher This Month

    Get the next $CET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CET
    $DAWN
    $RMAX

    CompanyDatePrice TargetRatingAnalyst
    Day One Biopharmaceuticals Inc.
    $DAWN
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    Day One Biopharmaceuticals Inc.
    $DAWN
    1/13/2026$34.00Buy
    TD Cowen
    Day One Biopharmaceuticals Inc.
    $DAWN
    8/19/2025$25.00Overweight
    Piper Sandler
    Day One Biopharmaceuticals Inc.
    $DAWN
    10/9/2024$32.00 → $33.00Buy
    Needham
    Day One Biopharmaceuticals Inc.
    $DAWN
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    Day One Biopharmaceuticals Inc.
    $DAWN
    4/24/2024$30.00 → $33.00Buy
    Needham
    RE/MAX Holdings Inc.
    $RMAX
    12/18/2023$16.00 → $14.00Neutral → Underweight
    JP Morgan
    RE/MAX Holdings Inc.
    $RMAX
    11/7/2023$19.50 → $9.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $CET
    $DAWN
    $RMAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Peterson Adam K

    4 - RE/MAX Holdings, Inc. (0001581091) (Issuer)

    4/2/26 4:41:50 PM ET
    $RMAX
    Real Estate
    Finance

    SEC Form 4 filed by Endeavor Foundation, Inc.

    4 - CENTRAL SECURITIES CORP (0000018748) (Issuer)

    3/30/26 12:19:37 PM ET
    $CET
    Finance/Investors Services
    Finance

    VP, CHIEF ACCOUNTING OFFICER Jenkins Leah R was granted 34,557 shares and covered exercise/tax liability with 4,717 shares, increasing direct ownership by 67% to 72,640 units (SEC Form 4)

    4 - RE/MAX Holdings, Inc. (0001581091) (Issuer)

    3/3/26 9:46:08 PM ET
    $RMAX
    Real Estate
    Finance

    $CET
    $DAWN
    $RMAX
    SEC Filings

    View All

    Amendment: SEC Form SC 14D9/A filed by Day One Biopharmaceuticals Inc.

    SC 14D9/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/14/26 6:03:28 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC TO-T/A filed by Day One Biopharmaceuticals Inc.

    SC TO-T/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/14/26 6:02:37 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC TO-T/A filed by Day One Biopharmaceuticals Inc.

    SC TO-T/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/8/26 6:01:16 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CET
    $DAWN
    $RMAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Hill John C bought $25,455 worth of shares (500 units at $50.91), increasing direct ownership by 0.65% to 77,373 units (SEC Form 4)

    4 - CENTRAL SECURITIES CORP (0000018748) (Issuer)

    1/6/26 11:04:52 AM ET
    $CET
    Finance/Investors Services
    Finance

    Amendment: CEO & President Hill John C bought $25,455 worth of shares (500 units at $50.91), increasing direct ownership by 0.65% to 77,373 units (SEC Form 4)

    4/A - CENTRAL SECURITIES CORP (0000018748) (Issuer)

    12/30/25 4:37:39 PM ET
    $CET
    Finance/Investors Services
    Finance

    CEO & President Hill John C bought $5,070 worth of shares (100 units at $50.70), increasing direct ownership by 0.39% to 73,277 units (SEC Form 4)

    4 - CENTRAL SECURITIES CORP (0000018748) (Issuer)

    11/12/25 1:55:09 PM ET
    $CET
    Finance/Investors Services
    Finance

    $CET
    $DAWN
    $RMAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

    3/19/26 10:00:00 AM ET
    $DAWN
    $ENGN
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Top-Producing Real Estate Brokerage in Rhode Island Aligns with REMAX for Agent-Focused Future

    Six-office, 300-agent former HomeSmart brokerage moves to REMAX for brand strength, global reach and technology advancementsDENVER, March 10, 2026 /PRNewswire/ -- REMAX®, the No. 1 name in real estate1, continues its growth mission and welcomes HomeSmart Professionals, one of the largest brokerages in Rhode Island to the REMAX brand. Owned and operated by Dean deTonnancourt, the brokerage will now operate as REMAX Revolution, bringing more than 300 agents from six offices into the network. REMAX, with more than 145,000 agents and more than 8,500 offices in over 120 countries and

    3/10/26 1:30:00 PM ET
    $RMAX
    Real Estate
    Finance

    Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

    Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion.SURESNES, France and BRISBANE, Calif., March 6, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One f

    3/6/26 10:21:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CET
    $DAWN
    $RMAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Day One Biopharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Day One Biopharmaceuticals from Buy to Neutral and set a new price target of $21.50

    3/10/26 8:39:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Day One Biopharmaceuticals with a new price target

    Piper Sandler initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $25.00

    8/19/25 8:33:40 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CET
    $DAWN
    $RMAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CET
    $DAWN
    $RMAX
    Leadership Updates

    Live Leadership Updates

    View All

    Top-Producing Real Estate Brokerage in Rhode Island Aligns with REMAX for Agent-Focused Future

    Six-office, 300-agent former HomeSmart brokerage moves to REMAX for brand strength, global reach and technology advancementsDENVER, March 10, 2026 /PRNewswire/ -- REMAX®, the No. 1 name in real estate1, continues its growth mission and welcomes HomeSmart Professionals, one of the largest brokerages in Rhode Island to the REMAX brand. Owned and operated by Dean deTonnancourt, the brokerage will now operate as REMAX Revolution, bringing more than 300 agents from six offices into the network. REMAX, with more than 145,000 agents and more than 8,500 offices in over 120 countries and

    3/10/26 1:30:00 PM ET
    $RMAX
    Real Estate
    Finance

    REMAX Canada Strengthens Commercial Division with Appointment of Damon Conrad as Vice President

    Seasoned leader to drive innovation and expansion in Canada's commercial real estate sector DENVER, Nov. 10, 2025 /PRNewswire/ -- REMAX®, the #1 name in real estate*, today announced the appointment of Damon Conrad as Vice President of Commercial for REMAX Canada. Conrad joins REMAX from Royal LePage Commercial, where he served as Vice President and General Manager, and brings more than 20 years of experience in commercial real estate, including with Cushman & Wakefield, Second Cup Coffee Co. and other prominent organizations. Based in Toronto, Conrad will lead REMAX Canada's

    11/10/25 4:35:00 PM ET
    $RMAX
    Real Estate
    Finance

    RE/MAX HOLDINGS, INC. WELCOMES TOM FLANAGAN AS CHIEF DIGITAL INFORMATION OFFICER

    DENVER, Sept. 22, 2025 /PRNewswire/ -- RE/MAX Holdings, Inc. (the "Company" or "RE/MAX Holdings") (NYSE:RMAX), parent company of REMAX, one of the world's leading franchisors of real estate brokerage services, and Motto Mortgage, the first and only national mortgage brokerage franchise brand in the U.S., proudly announces the hiring of Tom Flanagan as Chief Digital Information Officer, effective today. In this role, Flanagan will oversee all information technology and data operations across the Company and its affiliated brands. He will lead the engineering, data, and technolo

    9/22/25 4:30:00 PM ET
    $RMAX
    Real Estate
    Finance

    $CET
    $DAWN
    $RMAX
    Financials

    Live finance-specific insights

    View All

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RE/MAX HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    Total Fourth Quarter Revenue of $71.1 Million, Adjusted EBITDA of $22.4 MillionDENVER, Feb. 19, 2026 /PRNewswire/ --  Fourth Quarter 2025 Highlights(Compared to fourth quarter 2024 unless otherwise noted)Total Revenue decreased 1.8% to $71.1 millionRevenue excluding the Marketing Funds1 decreased 0.4% to $53.6 million, driven by a negative 0.4% organic revenue growth2 and flat foreign currency movementsNet income attributable to RE/MAX Holdings, Inc. of $1.4 million and income per diluted share (GAAP EPS) of $0.07Adjusted EBITDA3 decreased 4.0% to $22.4 million, Adjusted EBITDA

    2/19/26 4:15:00 PM ET
    $RMAX
    Real Estate
    Finance

    Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

    BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025. Live audio of the webcast will be accessible by visiting the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days follo

    2/10/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CET
    $DAWN
    $RMAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/14/24 4:30:11 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RE/MAX Holdings Inc.

    SC 13G/A - RE/MAX Holdings, Inc. (0001581091) (Subject)

    11/14/24 3:56:43 PM ET
    $RMAX
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by RE/MAX Holdings Inc.

    SC 13G/A - RE/MAX Holdings, Inc. (0001581091) (Subject)

    11/13/24 9:49:24 PM ET
    $RMAX
    Real Estate
    Finance